Results 21 to 30 of about 4,127 (170)
The Arab Journal of Interventional Radiology, 2023 Transarterial radioembolization (TARE) is a widely used treatment method for primary liver cancers and metastasis. Although TARE is relatively safe, it may cause liver abscess, failure, nontarget embolization, and vascular complications.
Muhammet Arslan +3 more
doaj +1 more source
Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma
Cureus, 2022 In recent years, combination therapies for hepatocellular carcinoma (HCC) have been increasingly used with superior treatment responses compared to monotherapies. However, the safety and efficacy of the transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) combinations for HCC patients have not been investigated in the ...
Vardar, Baran U +6 more
openaire +2 more sources
Transarterial radioembolization: a systematic review on gaining control over the parameters that influence microsphere distribution [PDF]
Drug Delivery, 2023 [Purpose] Transarterial radioembolization (TARE) is an established treatment modality for patients with unresectable liver cancer. However, a better understanding of treatment parameters that influence microsphere distribution could further improve the therapy.
T. J. Snoeijink +5 more
openaire +4 more sources
Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report [PDF]
Journal of Liver Cancer, 2022 There are various methods for treating advanced hepatocellular carcinoma with portal vein invasion, such as systemic chemotherapy, transarterial chemoembolization, transarterial radioembolization, and concurrent chemoradiotherapy.
In-Jung Kim +5 more
doaj +1 more source
Diagnostics, 2023 Background: Transarterial Radioembolization (TARE) is an effective treatment option for both primary and secondary liver malignancies. However, challenging anatomical conditions can lead to prolonged fluoroscopy times (FT), elevated doses of ...
Constantin Ehrengut +12 more
doaj +1 more source
Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma
Zhongliu Fangzhi Yanjiu, 2022 Primary hepatocellular carcinoma (HCC) is the sixth most common malignant tumor in the world, and ranks third in tumor-related deaths. The incidence and mortality of HCC in China are among the top five in both men and women, and are increasing year by ...
ZHOU Shi
doaj +1 more source
Locoregional Transarterial Therapies for Hepatocellular Carcinoma: Transarterial Chemoembolization and Radioembolization [PDF]
Visceral Medicine, 2013 <b><i>Background: </i></b>Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third most common cause of cancer-related mortality. Despite the widespread implementation of surveillance programs, more than half of the patients with HCC are diagnosed at late stages, when curative treatments ...
Mercedes Iñarrairaegui +2 more
openaire +1 more source
Side Effects of Yttrium-90 Radioembolization
Frontiers in Oncology, 2014 Limited therapeutic options are available for hepatic malignancies. Image guided targeted therapies have established their role in management of primary and secondary hepatic malignancies.
Ahsun eRiaz, Rafia eAwais, Riad eSalem
doaj +1 more source
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis [PDF]
Clinical and Molecular Hepatology, 2015 Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of diagnosis and its therapeutic options are very limited.
Hyun Young Woo, Jeong Heo
doaj +1 more source
Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies
Clinical and Translational Oncology, 2022 Transarterial radioembolization (TARE) with yttrium-90 (Y90) is a promising alternative strategy to treat liver tumors and liver metastasis from colorectal cancer (CRC), as it selectively delivers radioactive isotopes to the tumor via the hepatic artery, sparring surrounding liver tissue. The landscape of TARE indications is constantly evolving.
D. Viñal +4 more
openaire +3 more sources